-the Committee agreed that there was particular concern related to the safety of terfenadine containing medicinal products in relation to its arrhythmogenic potential and to its serious cardiac adverse effects for which various risk factors (including exceeding the recommended dose) have been identified and that, as a consequence, the safety of terfenadine may only be considered acceptable if it is used according to very strict instructions since association to any risk factor may lead to serious consequences.